Loading data for ADMA — first visit, this takes a few seconds.
ADMA Biologics Inc. (ADMA)
NasdaqGM: ADMA
· Real-Time Price · USD
9.34
-0.14 (-1.48%)
At close: Aug 28, 2026, 8:00 PM
9.52
+1.93%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
ADMA Biologics Inc. (ADMA) Stock Price, Analysis & Data
-1.48% (1D)
No data available
| Bid | 6.44 |
| Market Cap | 2.09B |
| Revenue (ttm) | 512.28M |
| Net Income (ttm) | 168.96M |
| 0.77 | |
| 0.7 | |
| 13.54 | |
| 9.51 | |
| P/B (ttm) | 5.16 |
| P/S (ttm) | 4.08 |
| Earnings Date | Nov 4, 2026 |
| Ask | 11.52 |
| Volume | 1,835,691 |
| Avg. Volume (20D) | 2,881,690 |
| Open | 9.46 |
| Previous Close | 9.48 |
| Day's Range | 9.34 - 9.51 |
| 52-Week Range | 7.21 - 20.46 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodef...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 17, 2013
Employees 640
Stock Exchange NasdaqGM
Ticker Symbol ADMA
Website https://www.admabiologics.com
Financial Performance
In 2025, ADMA Biologics's revenue was 510.17M, an increase of 19.63% compared to the previous year's 426.45M. Earnings were 146.93M, a decrease of -25.67%.
Financial StatementsEarnings Surprise
ADMA Biologics has released their quarterly earnings on Aug 5, 2026:
- Revenue of $124.39M misses estimates by $0, with 1.98% YoY growth.
- EPS of 0.17 exceeds estimates by 0.01, with 21.43% YoY growth.
ADMA Biologics Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade